BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37568730)

  • 1. Reverse Transcription Can Critically Impact the Diagnostic Outcome of
    Spiess B; Kleiner H; Tarnopolscaia I; Naumann N; Fabarius A; Hofmann WK; Saussele S; Seifarth W
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of
    Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
    Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
    Spiess B; Rinaldetti S; Naumann N; Galuschek N; Kossak-Roth U; Wuchter P; Tarnopolscaia I; Rose D; Voskanyan A; Fabarius A; Hofmann WK; Saußele S; Seifarth W
    PLoS One; 2019; 14(3):e0214305. PubMed ID: 30897165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
    Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
    Ross DM; Watkins DB; Hughes TP; Branford S
    Clin Chem; 2008 Sep; 54(9):1568-71. PubMed ID: 18641042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cDNA synthesis for BCR-ABL1 detection at the MMR level: the importance of using the appropriate kit.
    Chi J; Pierides C; Mitsidou A; Miltiadou A; Gerasimou P; Costeas P
    Biol Proced Online; 2015; 17(1):4. PubMed ID: 25667568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations.
    Ruiz MS; Sánchez MB; Vera Contreras YM; Agrielo E; Alonso M; Altuna ME; Anchordoqui MS; Asinari M; Bonetto ME; Camargo M; Giere I; González J; Granda Alacote AC; Guerra J; Gutiérrez M; Maldonado C; Makiya R; Manrique G; Monaco ME; Rozo JC; Santamaría C; Seravalle A; Zea O; Zubillaga MN; Mordoh J; Larripa I; Bianchini M
    Clin Chem Lab Med; 2020 Nov; 58(12):2025-2035. PubMed ID: 32374276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples.
    Stanoszek LM; Crawford EL; Blomquist TM; Warns JA; Willey PF; Willey JC
    J Mol Diagn; 2013 May; 15(3):391-400. PubMed ID: 23541592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of suitable housekeeping genes for gene expression studies in BCR-ABL1 positive B-lineage acute lymphoblastic leukemia.
    Gupta DG; Varma N; Kumar A; Naseem S; Sachdeva MUS; Bose P; Binota J; Gupta M; Sonam P; Rana P; Malhotra P; Varma S
    Mol Biol Rep; 2022 Jun; 49(6):4841-4848. PubMed ID: 35344115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of digital PCR in the detection of low abundance
    Yan Z; Sun Q; Zhang H; Han Y; Qiao J; Niu M; Zhu S; Zhao K; Wu Q; Cheng H; Cao J; Zeng L; Li Z; Xu K
    Oncol Lett; 2019 Nov; 18(5):5139-5144. PubMed ID: 31612025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR; Rempfer CB; Press RD
    Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of tyrosine kinase inhibitors based on
    Kim Y; Kim S; Lee JM; Ahn A; Yoo JW; Lee JW; Cho B; Chung NG; Kim Y; Kim M
    Front Pediatr; 2022; 10():928136. PubMed ID: 35967571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital PCR can provide improved
    Smitalova D; Dvorakova D; Racil Z; Romzova M
    Pract Lab Med; 2021 May; 25():e00210. PubMed ID: 33778144
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
    Alikian M; Gale RP; Apperley JF; Foroni L
    Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.
    Yoshida C; Nakamae H; Fletcher L; Koga D; Sogabe T; Matsumura I; Kanakura Y; Branford S; Naoe T
    Springerplus; 2016; 5():569. PubMed ID: 27247866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
    Salmon M; White HE; Zizkova H; Gottschalk A; Motlova E; Cerveira N; Colomer D; Coriu D; Franke GN; Gottardi E; Izzo B; Jurcek T; Lion T; Schäfer V; Venturi C; Vigneri P; Zawada M; Zuna J; Hovorkova L; Koblihova J; Klamova H; Markova MS; Srbova D; Benesova A; Polivkova V; Zackova D; Mayer J; Roeder I; Glauche I; Ernst T; Hochhaus A; Polakova KM; Cross NCP
    Leukemia; 2022 Jul; 36(7):1879-1886. PubMed ID: 35676453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
    May PC; Reid AG; Robinson ME; Khorashad JS; Milojkovic D; Claudiani S; ; Willis F; Apperley JF; Innes AJ
    BMC Med Genomics; 2023 Jul; 16(1):172. PubMed ID: 37496024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.